Search

Your search keyword '"Calvet, X"' showing total 208 results
Start Over Author "Calvet, X" Search Limiters Peer Reviewed
208 results on '"Calvet, X"'

1. Safety and effectiveness of direct-acting antiviral drugs in the treatment of hepatitis C in patients with inflammatory bowel disease

Author

Martin-Cardona, A., Horta, D., Florez-Diez, P., Vela, M., Mesonero, F., Ramos Belinchón, C., García, M.J., Masnou, H., de la Peña-Negro, L., Suarez Ferrer, C., Casanova, M.J., Durán, M. Ortiz, Peña, E., Calvet, X., Fernández-Prada, S.J., González-Muñoza, C., Piqueras, M., Rodríguez-Lago, I., Sainz, E., Bas-Cutrina, F., Mancediño Marcos, N., Ojeda, A., Orts, B., Sicilia, B., García, A. Castaño, Domènech, E., and Esteve, M.

Published
2024
Full Text
View/download PDF

2. Patients' perceptions of the impact of ulcerative colitis on social and professional life: results from the UC-LIFE survey of outpatient clinics in Spain

Author

Calvet X, Argüelles-Arias F, López-Sanromán A, Cea-Calvo L, Juliá B, Romero de Santos C, and Carpio D

Subjects
disease burden, patient-reported outcomes, patients’ perceptions, quality of life, ulcerative colitis, Medicine (General), R5-920
Abstract

Xavier Calvet,1–3 Federico Argüelles-Arias,4 Antonio López-Sanromán,5 Luis Cea-Calvo,6 Berta Juliá,6 Cristina Romero de Santos,6 Daniel Carpio7 1Hospital de Sabadell. Corporació Sanitària Universitària Parc Taulí, Sabadell, Spain; 2Centro de investigación biomédica en red de enfermedades hepáticas y digestivas (CIBEREHD), Spain; 3Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain; 4UGC Digestivo Intercentros Hospitales Virgen Macarena-Rocío, Seville, Spain; 5Section of Gastroenterology, Department of Gastroenterology and Hepatology, Hospital Ramón y Cajal, Madrid, Spain; 6Medical Affairs Department, Merck Sharp & Dohme, Madrid, Spain; 7Service of Gastroenterology Complexo Hospitalario Universitario de Pontevedra, Instituto de Investigación Biomedica (IBI), Pontevedra, Spain Purpose: Ulcerative colitis (UC) may cause many patients to miss out on important personal and professional opportunities. We therefore conducted a survey (UC-LIFE) to assess patients’ perceptions of the impact of UC on social and professional lives. Patients and methods: Consecutive unselected UC patients aged ≥18 years were recruited from 38 outpatient clinics in Spain. Patients completed the survey at home, returning it by post. The survey comprised 44 multiple-choice questions, including questions about the impact of UC on social, personal, professional, and academic activities. Results: Of 585 patients invited, 436 (75%) returned the survey (mean age 46 years; 47% women). High proportions of patients considered their disease “sometimes”, “frequently” or “mostly/always” influenced leisure activities (65.1%), recreational or professional activities (57.6%), or relationships with relatives or friends (9.9%). Patients also reported that UC influenced their decision to have children (17.2%), or their ability to take care of children (40.7%); these percentages were higher in women and in younger patients. Overall, 47.0% of patients declared that UC influenced the kind of job they performed, 20.3% had rejected a job due to UC, 14.7% had lost a job due to UC, and 19.4% had had academic problems due to UC. Conclusion: Beyond symptoms alone, UC imposes an enormous additional burden on patients’ social, professional, and family lives. This extra burden clearly needs to be addressed so that the ultimate goal of IBD treatment – normalization of patient quality of life – can be attained by as many patients as possible. Keywords: disease burden, patient-reported outcomes, patients’ perceptions, quality of life, ulcerative colitis

Published
2018

3. Post-operative morbidity and mortality of a cohort of steroid refractory acute severe ulcerative colitis: Nationwide multicenter study of the GETECCU ENEIDA Registry

Author

Ordás, I, Domènech, E, Mañosa, M, García-Sánchez, V, Iglesias-Flores, E, Rodríguez-Moranta, F, Márquez, L, Merino, O, Fernández-Bañares, F, Gomollón, F, Vera, M, Gutiérrez, A, LLaó, J, Gisbert, JP, Aguas, M, Arias, L, Rodríguez-Lago, I, Muñoz, C, Alcaide, N, Calvet, X, Rodríguez, C, Montoro, MA, García, S, De Castro, ML, Piqueras, M, Pareja, L, Ribes, J, Panés, J, Esteve, M, and on behalf of the ENEIDA registry of GETECCU

Published
2018
Full Text
View/download PDF

4. Disease severity in familial cases of IBD

Author

Andreu, M., Márquez, L., Domènech, E., Gisbert, J.P., García, V., Marín-Jiménez, I., Peñalva, M., Gomollón, F., Calvet, X., Merino, O., Garcia-Planella, E., Vázquez-Romero, N., Esteve, M., Nos, P., Gutiérrez, A., Vera, I., Cabriada, J.L., Martín, M.D., Cañas-Ventura, A., and Panés, J.

Published
2014
Full Text
View/download PDF

5. Phenotype and natural history of elderly onset inflammatory bowel disease: a multicentre, case‐control study

Author

Mañosa, M., Calafat, M., de Francisco, R., García, C., Casanova, M. J., Huelín, P., Calvo, M., Tosca, J., Fernández‐Salazar, L., Arajol, C., Zabana, Y., Bastida, G., Hinojosa, J., Márquez, L., Barreiro‐de‐Acosta, M., Calvet, X., Monfort, D., Gómez‐Garcia, M. R., Rodríguez, E., Huguet, J. M., Rojas‐Feria, M., Hervias, D., Atienza, R., Busquets, D., Zapata, E., Dueñas, C., Charro, M., Martínez‐Cerezo, F. J., Plaza, R., Vázquez, J. M., Gisbert, J. P., Cañete, F., Cabré, E., Domènech, E., Arajol, Clàudia, Atienza, Ramón, Barreiro‐de‐Acosta, Manuel, Bastida, Guillermo, Busquets, David, Calafat, Margalida, Calvet, Xavier, Calvo, Marta, Cabré, Eduard, Cañete, Fiorella, Casanova, Mª José, Charro, Mara, Dueñas, Carmen, Domènech, Eugeni, de Francisco, Ruth, Fernández‐Salazar, Luis, García, Carmen, Gómez‐Garcia, María Rosario, Hervias, Daniel, Hinojosa, Joaquín, Huelín, Patricia, Huguet, José Mª, Mañosa, Míriam, Márquez, Lucía, Martínez‐Cerezo, Francisco J., Monfort, David, Gisbert, Javier P., Plaza, Rocío, Rodríguez, Esther, Rojas‐Feria, María, Tosca, Joan, Vázquez, Juan M., Zabana, Yamile, and Zapata, Eva

Published
2018
Full Text
View/download PDF

8. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori

Author

Gisbert JP and Calvet X

Subjects
Diseases of the digestive system. Gastroenterology, RC799-869
Abstract

Javier P Gisbert1, Xavier Calvet21Department of Gastroenterology, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IP), and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain; 2Department of Gastroenterology, Hospital de Sabadell, Departament de Medicina, Universitat Autònoma de Barcelona and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, SpainBackground: Traditional standard triple therapy for Helicobacter pylori (H. pylori) infection (proton pump inhibitor-clarithromycin-amoxicillin) can easily be converted to non-bismuth quadruple (concomitant) therapy by the addition of a nitroimidazole twice daily.Aim: To critically review evidence on the role of non-bismuth quadruple therapy (proton pump inhibitor-clarithromycin-amoxicillin-nitroimidazole) in the treatment of H. pylori infection.Methods: Bibliographical searches were performed in MEDLINE and relevant congresses up to December 2011. We performed a meta-analysis of the studies evaluating the concomitant therapy, and of the randomized controlled trials comparing the concomitant and the standard triple therapy.Results: A meta-analysis of 19 studies (2070 patients) revealed a mean H. pylori cure rate (intention-to-treat) of 88% (95% confidence interval from 85% to 91%) for non-bismuth quadruple therapy. We performed a meta-analysis of the randomized controlled studies comparing the concomitant (481 patients) and the standard triple therapy (503 patients). The former was more effective than the latter: 90% versus 78% (intention-to-treat analysis). Results were homogeneous (I2 = 0%). The odds ratio for this comparison was 2.36 (95% confidence interval from 1.67 to 3.34). A tendency toward better results with longer treatments (7–10 days versus 3–5 days) has been observed, so it seems reasonable to recommend the length of treatment achieving the highest cure rates (10 days). Clarithromycin resistance may reduce the efficacy of non-bismuth quadruple therapy, although the decrease in eradication rates seems to be far lower than in standard triple therapy. Experience with the non-bismuth quadruple therapy in patients with metronidazole-resistant strains is still very limited.Conclusion: Non-bismuth quadruple (concomitant) therapy appears to be an effective, safe, and well-tolerated alternative to triple therapy and is less complex than sequential therapy. Therefore, this regimen appears well suited for use in settings where the efficacy of triple therapy is unacceptably low.Keywords: Helicobacter pylori, concomitant therapy, sequential therapy, clarithromycin, metronidazole, non-bismuth quadruple

Published
2012

10. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy

Author

Loras, C., Gisbert, J.P., Minguez, M., Merino, O., Bujanda, L., Saro, C., Domenech, E., Barrio, J., Andreu, M., Ordas, I., Vida, L., Bastida, G., Gonzalez-Huix, F., Piqueras, M., Ginard, D., Calvet, X., Gutierrez, A., Abad, A., Torres, M., Panes, J., Chaparro, M., Pascual, I., Rodriguez-Carballeira, M., Fernandez-Banares, F., Viver, J.M., and Esteve, M.

Subjects
Liver diseases -- Risk factors, Inflammatory bowel diseases -- Care and treatment, Inflammatory bowel diseases -- Patient outcomes, Immunosuppressive agents -- Usage, Immunosuppressive agents -- Health aspects, Hepatitis B -- Risk factors, Health
Published
2010

Catalog

Books, media, physical & digital resources
See catalog results